Title: C allele of rs479200 of the host EGLN1 gene - a risk factor for severe COVID-19 1 (pilot study) 2

- Authors: Renuka Harit¹, Sajal De^{#2}, Piyoosh Kumar Singh^{#1}, Deepika Kashyap¹, Manish 3 Kumar¹, Dibakar Sahu², Chander Prakash Yadav¹, Mradul Mohan¹, Vineeta Singh¹, 4 Ram Singh Tomar¹, Kailash C Pandey^{1,3*}, Kapil Vashisht^{1*} 5
- 6 ¹ ICMR-National Institute of Malaria Research, New Delhi
- ² All India Institute of Medical Sciences, Raipur, Chhattisgarh 7
- 8 ³ Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 9
- 10 #Authors contributed equally
- Correspondence: kapil@mrcindia.org, kailash.pandey@icmr.gov.in 11
- 12

Abstract 13

14 Background

15 Coronavirus disease-2019 (COVID-19) symptoms can range from asymptomatic, moderate to severe manifestations that result in an overall global case fatality rate of 2-7 %. While each 16 17 variant has had it challenges, and some variants are more severe than others, risk factors of severe COVID-19 are still under investigation. In this context, the host genetic predisposition 18 is also a crucial factor to investigate. In the present study, we investigated host genotypes of 19 the SNP rs479200 of the host EGLN1 gene, previously implicated in high altitude pulmonary 20 edema (HAPE), some of whose symptoms such as hypoxia profoundly overlap with severe 21 22 COVID-19.

Methods 23

After informed consent, 158 RT-PCR confirmed COVID-19 patients (March 2020 to June 24 25 2021) were enrolled in the study. Based on their clinical manifestations, disease severity was categorized by the clinical team. Blood samples were drawn and DNA was extracted from the 26 clot to infer different genotypes of the SNP rs479200 of the host EGLN1 gene. PCR-RFLP 27 28 analysis of the SNP rs479200 (C > T) was performed with an amplicon size of 367 bp. Various genotypes (TT, TC and CC) were assigned based on the presence/absence of a restriction site 29 (T/GTACA) for restriction enzyme BsrGI. Allele frequencies, Hardy-Weinberg Equilibrium 30 (HWE) and multinomial logistic regression were performed using statistical tool SPSS version 31 32 23 (IBM).

³⁴

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Findings 1

We observed that the severe COVID-19 category was composed of comparatively younger 2 3 patients with mean age (34.9±15.6), compared to asymptomatic and moderate categories whose 4 mean age was 49.7±17.9 and 54.3±15.7, respectively. Preponderance of males and high heterozygosity (TC) was observed across the clinical categories. Notably, the frequency of C 5 6 allele (0.664) was 2-fold higher than the T allele (0.336) in severe COVID-19 patients, whereas the allele frequencies were similar in asymptomatic and moderate category of COVID-19 7 patients. Multinomial logistic regression showed an association of genotypes with increasing 8 9 clinical severity; odds ratio (adjusted OR-11.414 (2.564-50.812)) and (unadjusted OR-6.214 (1.84-20.99)) for the genotype CC in severe category of COVID-19. Interestingly, the TC 10 11 genotype was also found to be positively associated with severe outcome (unadjusted OR-5.816 (1.489-22.709)), indicating association of C allele in imparting the risk of severe outcome. 12

13 Interpretation

- The study provides strong evidence that the presence of C allele of SNP (rs479200) of the 14
- 15 EGLN1 gene associates with severity in COVID-19 patients. Thus, the presence of C allele
- may be a risk factor for COVID-19 severity. This study opens new avenues towards risk 16
- assessment that include EGLN1 (rs479200) genotype testing and identifying patients with C 17
- allele who might be prioritized for critical care. 18

Keywords 19

20 EGLN1; COVID-19; PCR-RFLP; Genotype; SNPs, rs479200.

1 Introduction

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causal agent of 2 coronavirus disease-2019 (COVID-19). The continuous evolution of the virus has generated 3 different variants (Alpha, Beta, Gamma, Delta & Omicron) with their characteristic 4 transmission and virulence profile. The clinical disease symptoms vary drastically, majority of 5 the infections remain asymptomatic or moderate, often progressing to severe complications or 6 mortality ranging from 2-7 %¹. Symptoms of severe COVID-19 pneumonia may include acute 7 8 respiratory distress symptoms-hypoxia, dyspnea, hypocapnia or hypercapnia². However, the precise determinants of asymptomatic infections turning into severe disease are elusive. 9 Interestingly, the COVID-19 hypoxia partially overlaps with high altitude pulmonary edema 10 (HAPE) with some atypical features such as preserved lung compliance, intrapulmonary shunt 11 and mild dyspnea. These features indicate towards loss of the homeostatic oxygen-sensing 12 system which regulates oxygen uptake and systemic delivery. At molecular level, the 13 14 mitochondrial proteins had been altered during SARS-CoV-2 infection leading to plausible disruptions in oxygen-sensing mechanisms³. Several risk factors are being explored - both from 15 the virus and host origin; these broadly include age, gender, BMI and pre-existing 16 comorbidities⁴. Thorough investigations of the host genetic predisposition is crucial as several 17 genes have been reported to be associated with inflammation and immune responses and are 18 considered as risk factors⁴. Moreover, inter-individual variations in the effector or regulator 19 genes might play role in progression to severe disease. 20

21 Focusing on the narrative of COVID-19 hypoxia, EGLN1 is one of the gene that has been comprehensively studied in context of HAPE hypoxia⁵. The EGLN1 gene product- (2-22 23 oxoglutarate-dependent dioxygenase) regulates the hypoxia-inducible factor (HIF- α) via prolyl hydroxylation. Whereas in hypoxic conditions inactivation of EGLN1 leads to increased HIF-24 25 α and subsequent dimerization with HIF- β activate the hypoxia response elements (HRE) ^{6,7}. The HRE response may include, but is not limited to alterations in metabolic, cellular and 26 systemic responses inside the cells. Numerous studies in the literature have correlated the inter-27 individual variations of the EGLN1 gene (SNPs) in HAPE susceptibility ^{5,8,9}, aerobic capacity 28 ¹⁰, predisposition to preeclampsia ¹¹ in different ethnicities. The TT genotype of the rs479200 29 30 SNP of the EGLN1 gene has been shown to associate with HAPE susceptibility ⁵. The EGLN1 gene on chromosome 1 translates into a 426 amino acid protein ¹². Among the several 31 genotypes of the EGLN1 gene, six of them (rs2472261, rs480902, rs479200, rs2808611, 32 rs2153364, rs2491405) are present in the various ethnic populations of India ¹³. Specifically, 33

rs479200 and rs480902 SNPs have been repeatedly implicated for significant associations with 1 HAPE patients^{5,14}. Mishra et al.¹⁵ have observed a multi-fold increase in EGLN1 expression in 2 HAPE patients and significant association with the risk genotypes, their haplotypes and 3 interacting genotypes. The arterial oxygen saturation (SaO_2) levels were also found to be 4 5 inversely correlated with pulmonary artery systolic pressure (PASP) and EGLN1 expression. 6 SNPs from candidate genes have revealed significant differences of gene expression in HAPE 7 patients and healthy controls- ACE (rs4309), HSP70 (rs1008438), SP-A2 (rs1965708), PAI-1 (rs1799889), NOS (rs199983) and EGLN1 (rs480902) etc. ¹⁶. The seven polymorphisms of 8 9 EGLN1 gene- rs1538664, rs479200, rs2486729, rs2790879, rs480902, rs2486736 and 10 rs973252; were found to be significantly different in HAPE patients and HAPE controls¹⁴. A significant number of patients in severe COVID-19 mimic HAPE hypoxia¹⁷. 11

12 The lung transcriptome of COVID-19 patient implicated interaction of viral proteins ORF8 and OS9 with EGLN1 and EGLN2 genes with potential role in disrupting the EGLN1-HIF oxygen 13 14 sensor mechanism ^{18,19}. It is worth noting that EGLN1 gene acts as a natural regulator of the HIF- α protein and hence corroborates the hypothesis that inter-individual variations in the 15 EGLN1 gene might play role in the disease severity and subsequently risk assessment. 16 Interestingly, Roxadustat-HIF inhibitor shown to reduce ACE-2 expression, thereby inhibiting 17 entry and replication of SARS-CoV-2 inside lung epithelial cells, thus argued as potential 18 therapeutic agents for COVID-19²⁰. In the present study, categorized COVID-19 patients were 19 analyzed for the SNP rs479200 of the EGLN1 gene and potential associations of the genotype 20 with disease severity were investigated. 21

22

23 Material and methods

24 Sample collection and DNA isolation

Adult patients (age ≥ 18 years) with RT-PCR or Rapid Antigen Test positive for COVID-19 25 were included in the study. The patients were classified and defined by the clinical team as 26 asymptomatic COVID-19 cases (no hospitalization); moderate COVID-19 infection (requiring 27 oxygen support during hospitalization) and severe COVID-19 infection (required 28 29 invasive/non-invasive ventilator support for > 24hrs). Clotted blood samples of the COVID-19 patients were procured from the biorepository at ICMR-NIMR, Delhi and AIIMS, Raipur. 30 The study was approved by the Institutional Ethics Committees (IECs), AIIMS, Raipur 31 32 [1379/IEC-AIIMSRPR/2020] & ICMR-NIMR, Delhi [PHB/NIMR/EC/2020/145]. Nucleic

acid extractions were performed at the COVID-19 testing facility at ICMR-NIMR, Delhi, using 1

2 appropriate precautionary measures and personal protective equipment (PPE). DNA isolation

- from small fractions of the clotted blood was performed using DNeasy Blood and Tissue kit, 3
- Qiagen, Germany. Isolated DNA samples were quantified and purity was assessed using 4
- 5 Quawell UV-Vis Spectrophotometer Q5000.

Amplification for rs479200 and RFLP analysis 6

7 The EGLN1 gene sequence was retrieved from NCBI using Gene ID: 54583 for the egl-9 8 family hypoxia-inducible factor 1 [Homo sapiens (human)]. The reference SNP (rs479200) was identified from dbSNP Reference (rs) SNP report at the chromosomal position 9 chr1:231408034 (GRCh38.p13) with alleles G>A / G>C. A 367 bp segment of the EGLN1 10 gene covering the SNP rs479200 was amplified primers-FP-11 using 5`CTCCCAGCACATCTGTGAAT3` and RP- 5`TCGGATGGAAAGGTGGTAAAG3`. PCR 12 amplification of the SNP region rs479200 with the above primers was performed using 13 DreamTag PCR Mastermix (2x) (Thermo Scientific, USA) in following steps- 1) initial 14 denaturation [95 °C / 3 minutes, 2) denaturation 95 °C / 30 seconds, 3) annealing 55 °C / 30 15 seconds, 4) extension 72 °C/30 seconds, 5) steps 2-4 for 34 cycles and 5) final extension 72 16 °C / 5 minutes. The amplified products were visualized on 2% agarose gel and stored at 4 °C 17 until further use. 18

19 For RFLP analysis, the 367 bp amplicon containing the rs479200 was cut with restriction enzyme BsrGI (T/GTACA)¹¹. The reaction comprised-10x Cut Smart Buffer, 5 U BsrGI-HF 20 (New England Biolabs, USA), 100 ng of PCR amplicon containing rs479200 as template and 21 incubated at 37 °C for 30 minutes. The digested products were visualized on 2% agarose gel to 22 decipher the various genotypes of SNP rs4792000- homozygous (TT & CC), heterozygous 23 24 (TC).

Statistical analysis 25

The study data was fed in Microsoft Excel 365 and cross checked by two independent 26 researchers. The statistical and association analysis was performed using the SPSS version 23 27 (IBM). The statistical analysis included the chi-square, genotype and allele frequency, Hardy-28 29 Weinberg analysis. Further the multinomial regression was employed to test the association of demographic and genetic factors. 30

1 **Results**


2 Blood samples from 158 COVID-19 patients were tested by PCR-RFLP analysis to assess the genotypes of SNP rs479200 of the EGLN1 gene, using restriction enzyme BsrGI (T/GTACA). 3 Table 1 shows the demographic profiles of the patients included in the study, classified 4 according to the disease severity. In our study, the mean age of the total number of participants 5 6 was 45.9±18.3, however the mean age of severe COVID-19 patients was 34.9±15.6, contrary to the notion of prevalent severe complications in older patients. The mean age of COVID-19 7 8 patients in the asymptomatic and moderate disease was 49.7±17.9 and 54.3±15.7, respectively. In addition, preponderance of male COVID-19 patients was observed compared to females, 9 across the clinical categories and also in a total number of participants, but it is unclear if this 10 11 distribution is an attribute to social or biological causes.

		Asymptomatic		Moderate		Severe		Total	
	-	Ν	%	Ν	%	Ν	%	Ν	%
Age Mean ±SD		49.7±17.9		54.3±15.7		34.9±15.6		45.9±18.3	
Gender	Female	9	23.70%	11	17.70%	18	31.00%	38	22.75
Genuer	Male	29	76.30%	51	82.30%	40	69.00%	120	71.86

Table 1: Demographic profiles of the COVID-19 patients classified according to disease severity.

We then successfully amplified the EGLN1 gene segment (367 bp), flanking the SNP
rs479200 (367 bp) from the DNA isolated from clotted blood of the COVID-19 patients (Fig.


16 **1**).



17

18 Figure 1: SNP rs479200 of the EGLN1 gene amplified from DNA isolated from clotted blood samples.

- Further, PCR-RFLP analysis revealed the genotypes of the SNP rs479200 of the EGLN1 gene 1
- (Fig. 2)- TT genotype due to absence of 'C' at restriction site and hence no digestion (367 bp) 2
- by the restriction enzyme; CC genotype due to the presence of 'C' at restriction site leading to 3
- complete digestion (269 + 98 bp); TC genotype due to the presence of 'C' at restriction site, 4
- 5 only in one allele and incomplete digestion conferring heterozygous allele (367 + 269 + 98 bp).



6

7 Figure 2: PCR-RFLP analysis of SNP rs479200 of EGLN1 gene with enzyme BsrGI (T/GTACA).

8 The genotypes, allele frequencies of the EGLN1 gene rs479200 (T/C) and Hardy-Weinberg Equilibrium (HWE) of the study population are summarized in **Table 2**. The data showed high 9 heterozygosity across the clinical categories and in the total number of study patients. It was 10 observed that both the alleles (T & C) were uniformly present in the total study patients with a 11 high proportion of ancestral T allele, except for the severe category patients. The frequency of 12 13 'C' allele (0.664) was observed to be 2-fold higher in proportion than the 'T' allele (0.336). The allele frequencies were in HWE status across the disease categories. 14

medRxiv preprint doi: https://doi.org/10.1101/2022.03.11.22272214; this version posted March 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-I	-ND 4.0 International license .
---	---------------------------------

			Gender Classification		ssification			
			Female	Male	Asymptomatic	Moderate	Severe	Total
	TT	Ν	11	21	12	16	7	35
		%	28.20%	17.10%	31.60%	25.80%	10.40%	20.96%
Construes	тс	Ν	20	61	18	33	31	82
Genotypes	IC	%	51.30%	49.60%	47.40%	53.20%	46.30%	49.10%
	CC ·	Ν	8	41	8	13	29	50
		%	20.50%	33.30%	21.10%	21.00%	43.30%	29.94%
Chi square (p-value)		lue)	3.484 (.175)		13.274 (.010*)			
Alleles	Т		0.538	0.419	0.553	0.524	0.336	0.455
Anteles	С		0.462	0.581	0.447	0.476	0.664	0.545
HW equilibrium		0.039	0.044	0.067	0.278	0.093	0.01662	
p-value		0.843	0.835	0.796	0.598	0.761	0.89741	

1 2 3 **Table 2:** Genotypes, allele frequencies and Hardy–Weinberg Equilibrium (HWE) of the
COVID-19 study patients.

Multinomial logistic regression was performed in an adjusted and unadjusted model to test the 4 association of genotype variables with clinical severity. Moderate and severe COVID-19 5 patients were compared with the asymptomatic patients, separately. In the unadjusted model 6 7 the effects of genotype and disease severity were inferred, while the adjusted model, the genotypes were tested in isolation for their association with moderate and severe clinical 8 9 outcomes. Table 3 depicts the association analysis data, highlighting the association of 10 genotype (CC) and genotype (TC) with severe outcome in COVID-19. The highest odds ratio (11.414 (2.564-50.812)) was observed with genotype (CC) in the adjusted model in 11 12 asymptomatic vs severe COVID-19 subject's comparison; however, the unadjusted model genotype (CC) shows the odds ratio of 6.214 (1.84-20.99). The heterozygous genotype (TC) 13 was also found to be positively associated with disease severity (unadjusted OR-5.816 (1.489-14 22.709)). The genotypes did not demonstrate any association in the comparison scenario of 15 moderate vs asymptomatic patients. 16

medRxiv preprint doi: https://doi.org/10.1101/2022.03.11.22272214; this version posted March 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license
--

Variable (genotypes)		B- coefficient	Wald (Sig.)	Odds Ratio (CI)		
Asymptomatic Vs Moderate						
$C_{\text{on otrue}}(CC)$	Adjusted	0.077	0.016 (0.9)	1.08 (0.326-3.576)		
Genotype (CC)	Unadjusted	0.198	0.113 (0.737)	1.219 (0.384-3.871)		
$C_{\rm op}$ of two (TC)	Adjusted	0.199	0.162 (0.688)	1.22 (0.463-3.215)		
Genotype (TC)	Unadjusted	0.318	0.438 (0.508)	1.375 (0.535-3.532)		
Asymptomatic Vs Severe						
Construe (CC)	Adjusted	2.435	10.213 (0.001)	11.414 (2.564-50.812)		
Genotype (CC)	Unadjusted	1.827	8.653 (0.003)	6.214 (1.84-20.99)		
Construe (TC)	Adjusted	1.761	6.417 (0.011)	5.816 (1.489-22.709)		
Genotype (TC)	Unadjusted	1.083	3.733 (0.053)	2.952 (0.984-8.854)		

1 **Reference genotype (TT)**

Table 3: Multinomial logistic regression to infer the association of genotypes with disease severity.

4 Discussion

Whilst there is a consensus that severe COVID-19 patients present acute respiratory distress, 5 mimicking attributes of high altitude pulmonary edema (HAPE)². However, the similarities in 6 7 the pathophysiology of severe COVID-19 and HAPE are debatable ²¹. Failure of respiratory homeostasis in acute respiratory distress syndrome (ARDS), severe COVID-19 and HAPE 8 include variable hypoxia, dyspnoea, hypoxic pulmonary vasoconstriction (HPV), 9 Ventilation/perfusion (V/Q) mismatch, pulmonary hypertension, pulmonary capillary pressure 10 and reduced lung compliance ¹. HIF- α is shown to be central to the oxygen-sensing mechanism 11 recruited by cells in response to hypoxia, whose expression is regulated by 2-oxoglutarate-12 dependent dioxygenase (20DD- a product of EGLN1 gene); acting as a natural inhibitor of 13 HIF-α. In normoxic conditions, a balanced proteasomal degradation of constitutively expressed 14 HIF-1a induced by 20DD abrogates the translocation of HIF-1a and HIF-B dimer to activate 15 16 HRE transcription. However, in a hypoxic scenario the balance of 2ODD and HIF-1α skews towards overproduction of HIF-1 α , leading to dimerization with HIF- β and transcriptional 17 18 activation of HRE²². Higher levels of HIF- α have also been shown to induce higher expression 19 of angiotensin-converting enzyme-2 (ACE-2) receptor on cell surface facilitating the viral entry in the case of SARS-CoV-2. Further, complicating the situation are the interindividual 20 variations of the EGLN1 gene, that have been observed to be responsible for varying 21 22 capabilities in coping with the anti-hypoxic responses.

23 The present study investigated the EGLN1 genotypes in asymptomatic, moderate and severe

24 COVID-19 patients at the time of diagnosis. Particularly, SNP rs479200 of the EGLN1 gene


that was previously found to be associated with HAPE susceptibility, aerobic capacity and

predisposition to pre-eclampsia in multiple studies was explored further; where in SNP 1 2 rs479200 (C>T) results in three distinct genotypes-homozygous (CC & TT) and heterozygous (TC), with C & T as major and minor alleles, respectively. Statistical analysis SNP rs479200 3 revealed that both the alleles are present in equal proportion in asymptomatic and moderate 4 5 categories of COVID-19 patients, but overrepresentation of C allele (2-fold higher than T 6 allele) in severe COVID-19 was peculiar. The CC genotype was significantly overrepresented 7 in severe COVID-19 patients (p-value = 0.047). Multinomial logistic regression was performed to evaluate the association of different genotypes with disease severity, which estimated (OR-8 9 11.414 (2.564-50.812)- adjusted) and (OR- 6.214 (1.84-20.99)- unadjusted) for genotype CC, in asymptomatic vs severe categories of COVID-19. Moreover, the TC genotype was also 10 found to be strongly associated with severe COVID-19, indicating the role of the C allele as a 11 12 risk factor.

Transcription of the hypoxia response elements (HRE) in normoxic conditions is regulated and 13 14 mediated by 20DD- a gene product of EGLN1 gene, however in hypoxic conditions, inactive 20DD cannot inhibit HIF- α and HIF- β dimerization leading to activation of HRE (Fig. 3a, b) 15 Considering the genotype data of the EGLN1 gene, TT genotype is correlated with higher 16 expression of EGLN1 gene resulting in overproduction of 2ODD ⁵ and conversely, the CC 17 genotype results in lower expression of EGLN1 gene producing less 20DD. Accordingly, 18 Aggarwal et al.⁵ previously showed that individuals residing at low altitudes with TT genotype 19 do not respond well in hypoxic conditions succumbing to HAPE at high altitudes. 20 Overproduction of 2ODD in the presence of T allele (Fig. 3c) results in minimal HIF- α levels, 21 22 rendering the individuals hypo-responsive towards hypoxia. In contrast, the ancestral CC genotype in highlanders imparts a physiological adaptation to respond well in hypoxic 23 conditions. Notably, Callele- the identified risk factor in severe COVID-19, producing inactive 24 20DD in hypoxic conditions, accumulates high levels of HIF-a making them hyper-responsive 25 towards hypoxia with activation of HRE (Fig. 3d). The hyper-responsiveness towards hypoxia 26 27 might explain the severe COVID-19 manifestations- pulmonary vascular alterations, overproduction of inflammatory cytokines, fluid accumulation in alveoli and the cytokine 28 29 storm.

Thus, the hypothesis above postulates that individuals with severe COVID-19 symptoms and the C allele (risk factor), make them hyper-responsive in hypoxic conditions and progress towards worsening the respiratory hemodynamics and inflammatory pathways. To strengthen the hypothesis of C allele as a risk factor a larger cohort of categorized COVID-19 patients

- 1 must be investigated in different settings. It is worth noting that deducing the genotype of SNP
- 2 rs479200 can be easily accomplished in 4-6 hours' time, equivalent to a COVID-19 RT-PCR
- 3 test. Therefore, the presence of C allele as a risk factor in severe COVID-19 might serve as a
- 4 feasible risk assessment prognostic marker and prioritization of limited medical infrastructure
- 5 in view of COVID-19 waves, as0020witnessed globally002E



- Figure 3: Schematic representation of interplay between HIF-α and 2ODD (product of EGLN1 gene), inhibiting activation of HRE in normoxic (a) and activation of HRE via dimerization with HIF-β in hypoxic (b) conditions. The postulated effect of T-allele
 (c) in COVID-19 hypoxia weakening the HRE activation and effect of C-allele (d) in the heightened HRE activation. (Created by BioRender trial version)
- 11 (2ODD- 2-oxoglutarate-dependent dioxygenase; HIF-α- Hypoxia inducible factor- α; HIF-β 12 Hypoxia inducible factor-β; HRE- Hypoxic response elements.)
- 13

1 Acknowledgement

- 2 This work was funded by intramural funding support from ICMR-NIMR, Delhi. We thank Drs.
- 3 Amit Sharma and O. P. Singh for their critical feedback in the study. We thank the NIMR
- 4 biorepository team members for procuring the COVID-19 infected patient samples during the
- 5 first wave in India. The publication bears the NIMR publication committee no. RIC-11/2022.
- 6 We thank Mr. Puneet Saini and Ramakant Pal from ICMR-NIMR, stores for timely
- 7 procurement of reagents in unprecedented COVID-19 lockdown situation.

8 Conflict of Interest

9 Authors declare no conflict of interest.

10 Author contributions

- 11 Conceived and designed the experiments: KV, KCP, SD
- 12 Data generation and analysis: RH, PKS, DK, MK, DS, CPY, MM, VS, RST, KV, KCP
- 13 Data interpretation, manuscript writing and review: KV, KCP, PKS, CPY, VS, MM, SD

1 Bibliography

- Archer, S. L., Sharp, W. W. & Weir, E. K. Differentiating COVID-19 Pneumonia from
 Acute Respiratory Distress Syndrome and High Altitude Pulmonary Edema:
 Therapeutic Implications. *Circulation* 142, 101–104 (2020).
- Gattinoni, L. *et al.* COVID-19 pneumonia: different respiratory treatments for different phenotypes? *Intensive Care Med.* 46, 1099–1102 (2020).
- Lai, C. C. *et al.* Proteomic analysis of up-regulated proteins in human promonocyte
 cells expressing severe acute respiratory syndrome coronavirus 3C-like protease. *Proteomics* 7, 1446–1460 (2007).
- Velavan, T. P. *et al.* Host genetic factors determining COVID-19 susceptibility and severity. *EBioMedicine* 72, (2021).
- Aggarwal, S. *et al.* EGLN1 involvement in high-altitude adaptation revealed through
 genetic analysis of extreme constitution types defined in Ayurveda.
 doi:10.1073/pnas.1006108107.
- Semenza, G. L. Regulation of oxygen homeostasis by hypoxia-Inducible factor 1.
 Physiology vol. 24 97–106 (2009).
- Jahani, M., Dokaneheifard, S. & Mansouri, K. Hypoxia: A key feature of COVID-19
 launching activation of HIF-1 and cytokine storm. *J. Inflamm. (United Kingdom)* 17,
 1-10 (2020).
- Lü, P., Fan, J. & Xi, H. J. Association of polymorphisms of rs479200 and rs480902 in
 EGLN1 gene with hypoxia adaptation in high altitude in Tibetans. *Acta Anat. Sin.* 44, 419–422 (2013).
- 9. Yasukochi, Y., Nishimura, T., Motoi, M. & Watanuki, S. Association of EGLN1
 genetic polymorphisms with SpO 2 responses to acute hypobaric hypoxia in a Japanese
 cohort. J. Physiol. Anthropol. 37, 1–12 (2018).
- Brutsaert, T. D. *et al.* Association of EGLN1 gene with high aerobic capacity of
 Peruvian Quechua at high altitude. *Proc. Natl. Acad. Sci. U. S. A.* 116, 24006–24011
 (2019).
- Kumar K. S., P., Arcot, M., Munisamaiah, M. & Balakrishna, S. Novel association of
 SNP rs479200 in EGLN1 gene with predisposition to preeclampsia. *Gene* 705, 1–4
 (2019).
- Tweedie, S. *et al.* Genenames.org: The HGNC and VGNC resources in 2021. *Nucleic Acids Res.* 49, D939–D946 (2021).
- 34 13. IGVDB.
 35 http://www.igvdb.res.in/searchcard.php?page_no=6&choice=200&sort=GENESYMB
 36 OL.
- Horiuchi, T. *et al.* Gene-Gene Interaction between EPAS1 and EGLN1 in Patients with
 High-Altitude Pulmonary Edema. in *European Respiratory Journal* vol. 52 PA3060
 (European Respiratory Society (ERS), 2018).
- 40 15. Mishra, A., Mohammad, G., Thinlas, T. & Pasha, M. A. Q. EGLN1 variants influence
 41 expression and Sao2 levels to associate with high-altitude pulmonary oedema and

1		adaptation. <i>Clin. Sci.</i> 124 , 479–489 (2013).
2 3 4	16.	Wu, A. <i>et al.</i> Correlation between single nucleotide polymorphisms in hypoxia-related genes and susceptibility to acute high-altitude pulmonary edema. <i>Genet. Mol. Res.</i> 14 , 11562–11572 (2015).
5 6	17.	Gattinoni, L. <i>et al.</i> Intensive Care Medicine COVID-19 pneumonia: different respiratory treatment for different phenotypes? doi:10.1007/s00134-020-06033-2.
7 8 9 10	18.	Bashar, A., Khademul Islam, M. M. & Khan, AAK. Lung transcriptome of a COVID-19 patient and systems biology predictions suggest impaired surfactant production which may be druggable by surfactant therapy. (2020) doi:10.1038/s41598-020-76404-8.
11 12	19.	Ivan, M. & Kaelin, W. G. The EGLN-HIF O2-Sensing System: Multiple Inputs and Feedbacks. <i>Mol. Cell</i> 66 , 772–779 (2017).
13 14	20.	Wing, P. A. C. <i>et al.</i> Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells. <i>Cell Rep.</i> 35 , (2021).
15 16 17	21.	Luks, A. M. & Swenson, E. R. COVID-19 lung injury and high altitude pulmonary edema: A false equation with dangerous implications. <i>Ann. Am. Thorac. Soc.</i> 17 , 918–921 (2020).
18 19	22.	Poloznikov, A. A. <i>et al.</i> HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons. <i>Front. Pharmacol.</i> 11 , 2522 (2021).